TALOPH(SH:600222) Xin Lang Zheng Quan·2025-12-29 03:12Core Viewpoint - TaiLong Pharmaceutical experienced a stock price decline of 2.06% on December 29, with a current price of 6.65 CNY per share and a market capitalization of 3.816 billion CNY [1] Group 1: Financial Performance - For the period from January to September 2025, TaiLong Pharmaceutical reported a revenue of 1.187 billion CNY, representing a year-on-year decrease of 11.47% [2] - The net profit attributable to the parent company for the same period was 25.3255 million CNY, down 12.36% year-on-year [2] - The company has distributed a total of 112 million CNY in dividends since its A-share listing, with 15.5307 million CNY distributed over the last three years [3] Group 2: Stock Market Activity - The stock price of TaiLong Pharmaceutical has increased by 30.65% year-to-date, but has seen a decline of 5.41% over the last five trading days and 9.77% over the last 20 days [1] - The company has appeared on the "Dragon and Tiger List" three times this year, with the most recent appearance on December 10, where it recorded a net buy of -8.4516 million CNY [1] - As of September 30, 2025, the number of shareholders decreased to 40,400, while the average circulating shares per person increased by 1.09% to 14,190 shares [2] Group 3: Business Overview - TaiLong Pharmaceutical, established on August 31, 1998, operates in the pharmaceutical manufacturing sector, focusing on traditional Chinese medicine, chemical drug manufacturing, and pharmaceutical wholesale [2] - The company's revenue composition includes 70.59% from drug manufacturing, 14.71% from drug research services, and 14.42% from drug material circulation [2] - The company is categorized under the pharmaceutical and biological industry, specifically in traditional Chinese medicine [2]